Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Valmen Monzani"'
Autor:
Silvia Consalvi, Chiara Mozzetta, Paolo Bettica, Massimiliano Germani, Francesco Fiorentini, Francesca Del Bene, Maurizio Rocchetti, Flavio Leoni, Valmen Monzani, Paolo Mascagni, Pier Lorenzo Puri, Valentina Saccone
Publikováno v:
Molecular Medicine, Vol 19, Iss 1, Pp 79-87 (2013)
Abstract Previous work has established the existence of dystrophin-nitric oxide (NO) signaling to histone deacetylases (HDACs) that is deregulated in dystrophic muscles. As such, pharmacological interventions that target HDACs (that is, HDAC inhibito
Externí odkaz:
https://doaj.org/article/228636ca172f4dd983eb3ef54f6caf4d
Autor:
Jennifer H. Mahaffey, Maria A. Cavasin, T. Brett Reece, Ying H. Lin, Henk Granzier, Charles A. Dinarello, Mark Y. Jeong, Chandrasekhar Saripalli, Kimberly M. Demos-Davies, Sara A. Wennersten, Valmen Monzani, Paolo Mascagni, Timothy A. McKinsey, Amrut V. Ambardekar
Publikováno v:
Science Translational Medicine, 10, 427
Science Translational Medicine, 10
Science Translational Medicine, 10
There are no approved drugs for the treatment of heart failure with preserved ejection fraction (HFpEF), which is characterized by left ventricular (LV) diastolic dysfunction. We demonstrate that ITF2357 (givinostat), a clinical-stage inhibitor of hi
Autor:
Flavio Leoni, Valmen Monzani, Charles A. Dinarello, Antonio Furlan, Daniela Modena, Leonid L. Reznikov, Paolo Mascagni, Gianluca Fossati
Publikováno v:
Molecular Medicine, 17, 353-62
Molecular Medicine, 17, 5-6, pp. 353-62
Molecular Medicine, 17, 5-6, pp. 353-62
Contains fulltext : 97219.pdf (Publisher’s version ) (Open Access) ITF2357 (givinostat) is a histone deacetylase inhibitor with antiinflammatory properties at low nanomolar concentrations. We report here a phase I safety and pharmacokinetics trial
Autor:
Nicolai Juul Birkbak, Morten Lundh, Christopher T. Workman, Steven Paraskevas, Susanne Mandrup, Søren Fisker Schmidt, Reid Aikin, Lykke Blaabjerg, Lars Groth Grunnet, Daniel Noesgaard, Dan Ploug Christensen, Paolo Mascagni, Gianluca Fossati, Conny Gysemans, Chantal Mathieu, Thomas Mandrup-Poulsen, Nils Billestrup, Mattias S. Dahllöf, Valmen Monzani, Lorenzo Piemonti, Charles A. Dinarello
Publikováno v:
Christensen, D P, Gysemans, C, Lundh, M, Dahllöf, M S, Noesgaard, D, Schmidt, S F, Mandrup, S, Birkbak, N, Workman, C, Piemonti, L, Blaabjerg, L, Monzani, V, Fossati, G, Mascagni, P, Paraskevas, S, Aikin, R A, Billestrup, N, Grunnet, L G, Dinarello, C A, Mathieu, C & Mandrup-Poulsen, T 2014, ' Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection ', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 3, pp. 1055-9 . https://doi.org/10.1073/pnas.1320850111
Proceedings of the National Academy of Sciences USA, 111, 1055-9
Proceedings of the National Academy of Sciences USA, 111, 3, pp. 1055-9
Proceedings of the National Academy of Sciences USA, 111, 1055-9
Proceedings of the National Academy of Sciences USA, 111, 3, pp. 1055-9
Type 1 diabetes is due to destruction of pancreatic β-cells. Lysine deacetylase inhibitors (KDACi) protect β-cells from inflammatory destruction in vitro and are promising immunomodulators. Here we demonstrate that the clinically well-tolerated KDA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e178acbef1a94c9140cc523ffbad3fd
https://hdl.handle.net/20.500.14017/46c8e1ed-c60c-4e1d-9bc2-1e66acc3ab5e
https://hdl.handle.net/20.500.14017/46c8e1ed-c60c-4e1d-9bc2-1e66acc3ab5e
Publikováno v:
Journal of Cardiovascular Pharmacology. 26:S72-79
To evaluate the safety and pharmacologic activity of ITF 296 in humans, three groups of healthy male normotensive subjects were studied. The first two groups (six subjects each) received, in ascending order, three dose levels of ITF 296 by 30-min int
Autor:
Francesco Cilurzo, Giorgio Bertolini, Andrea Zaliani, Antonella Casiraghi, Luisa Montanari, M. Valmen Monzani, Paola Minghetti
Publikováno v:
Farmaco (Societa chimica italiana : 1989). 55(8)
The aim of this work was to correlate the in vitro human skin permeability, expressed as the permeability coefficient ( K p ), and some physicochemical parameters of a new series of benzoxazinones. The in vitro human skin permeability of 14 substance
Autor:
Chiara Mozzetta, Pier Lorenzo Puri, Flavio Leoni, Paolo Bettica, Silvia Consalvi, Francesco Fiorentini, Valentina Saccone, Maurizio Rocchetti, Francesca Del Bene, Paolo Mascagni, Massimiliano Germani, Valmen Monzani
Publikováno v:
Molecular Medicine; Vol 19
Previous work has established the existence of dystrophin-nitric oxide (NO) signaling to histone deacetylases (HDACs) that is deregulated in dystrophic muscles. As such, pharmacological interventions that target HDACs (that is, HDAC inhibitors) are o
Autor:
Paolo Mascagni, Silvia Consalvi, Valmen Monzani, F. Del Bene, Pier Lorenzo Puri, Massimiliano Germani, Paolo Bettica, Valentina Saccone, Chiara Mozzetta
Publikováno v:
Neuromuscular Disorders. 22:847
Inhibition of Histone Deacetylases (HDAC) has beneficial effects in mouse models of muscular dystrophies indicating that HDACs are a potential pharmacological target for Duchenne Muscular Dystrophy (DMD). We have studied the effects of Givinostat, a
Publikováno v:
Cytokine. 48:120
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.